Flagship Pioneering

Apriori Bio is working to create a humanity that is protected against viral threats.

ProFound Therapeutics is focused on advancing the understanding of biology and disease through its innovative therapeutic target discovery platform. This platform employs protein detection technologies to systematically identify and validate proteins, allowing for a comprehensive analysis of their therapeutic potential. By creating a database that encompasses tens of thousands of novel proteins, ProFound Therapeutics facilitates biotech researchers in exploring the connectivity, functionality, and roles of these proteins in health and disease. This approach aims to enable the development of therapeutics that were previously unattainable, contributing to significant advancements in the field of biotechnology.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.

Generate Biomedicines, Inc. develops a platform to invent novel antibodies, peptides, enzymes, receptors, and other therapeutic proteins. It offers Generative Biology, a machine learning based solution that learns from all known proteins in order to encode and apply the fundamental principles of how genetic sequences lead to protein structure and function for creating novel protein sequences with optimized therapeutic potential. Its Generative Biology is applied to all protein modalities and generate novel proteins with desired functions and solutions that interact potently and specifically with therapeutic targets. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in March 2020. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.

CIBO Technologies, Inc. is a software company focused on enhancing agricultural practices through advanced modeling and simulation of agricultural ecosystems. The company offers a range of products, including Continuum DB, for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; and WhetherRain, a stochastic weather generator that provides detailed weather simulations. Additionally, CIBO provides DirtPatch for environmental reconstruction and TerraFarm for planetary-scale simulations. Their Land Intelligence platform generates insights for agricultural stakeholders, including farmers, investors, and lenders, and covers a variety of crops such as corn, soy, and wheat. By combining science, data, and technology, CIBO aims to bring transparency and valuable insights to the agriculture value chain, thereby supporting sustainable practices and informed decision-making across the agricultural landscape. Founded in 2015 and headquartered in Massachusetts, CIBO also maintains offices in Missouri, Michigan, and Minnesota.

Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies through its proprietary viral vector platform known as Anellovector. Founded in 2017, the company harnesses the biology of the human commensal virome to create redosable and targetable DNA therapies. This approach addresses significant limitations associated with traditional gene therapies, such as restricted access to various tissues, challenges with redosing, risks of genomic integration, and issues related to tolerability. By expanding the applications of gene therapy beyond simple gene replacement, Ring Therapeutics aims to treat a broader range of diseases that have previously been difficult to address. The company was formerly known as VL46, Inc. until its name change in November 2018.

Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Inari Agriculture, Inc. is a biotechnology company that specializes in developing customized seeds through CRISPR gene editing technology, aimed at optimizing crop growth in diverse environmental conditions. Founded in 2016 and based in Cambridge, Massachusetts, Inari focuses on crops such as wheat, soybean, and corn, addressing significant agricultural challenges like climate change. The company employs advanced multiplex gene editing and predictive design to create efficient and sustainable plant breeding solutions, thereby reducing the time and cost associated with traditional breeding methods. Inari's approach aims to enhance agricultural productivity while respecting environmental sustainability, and it collaborates with a diverse team of scientists and partners globally to drive innovation in the agricultural sector.

Laronde is pioneering a platform that offers a completely novel way of modulating human biology. Endless RNA™ (eRNA), is a uniquely engineered RNA that can be programmed to express diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidly scaling to support the parallel development of multiple programs across many disease areas.

Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Cellarity Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing medicines by analyzing cell behaviors. Established in 2017, it utilizes a proprietary platform that digitizes molecular information within cells, shedding light on their functions in both health and disease. By employing advanced single-cell technologies and machine learning algorithms, Cellarity's platform quantifies and elucidates cellular behaviors, enabling a deeper understanding of the complex networks that govern these processes. This innovative approach aims to enhance the efficiency and success rate of drug discovery, allowing for more effective targeting of diseases at the cellular and molecular levels.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Valo Health is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing treatments.

Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.

Generate Biomedicines, Inc. develops a platform to invent novel antibodies, peptides, enzymes, receptors, and other therapeutic proteins. It offers Generative Biology, a machine learning based solution that learns from all known proteins in order to encode and apply the fundamental principles of how genetic sequences lead to protein structure and function for creating novel protein sequences with optimized therapeutic potential. Its Generative Biology is applied to all protein modalities and generate novel proteins with desired functions and solutions that interact potently and specifically with therapeutic targets. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in March 2020. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Ohana Biosciences, Inc.,a biotechnology company, develops novel molecular techniques of fertility treatment. manufactures reproductive medicines to improve sperm quality and function to address infertility, prevent inherited disease, and produce a long-acting, reversible, and non-hormonal male contraceptive. The company was formerly known as VL34, INC. and changed its name to Ohana Biosciences, Inc. in February 2017. Ohana Biosciences, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies through its proprietary viral vector platform known as Anellovector. Founded in 2017, the company harnesses the biology of the human commensal virome to create redosable and targetable DNA therapies. This approach addresses significant limitations associated with traditional gene therapies, such as restricted access to various tissues, challenges with redosing, risks of genomic integration, and issues related to tolerability. By expanding the applications of gene therapy beyond simple gene replacement, Ring Therapeutics aims to treat a broader range of diseases that have previously been difficult to address. The company was formerly known as VL46, Inc. until its name change in November 2018.

Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Cellarity Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing medicines by analyzing cell behaviors. Established in 2017, it utilizes a proprietary platform that digitizes molecular information within cells, shedding light on their functions in both health and disease. By employing advanced single-cell technologies and machine learning algorithms, Cellarity's platform quantifies and elucidates cellular behaviors, enabling a deeper understanding of the complex networks that govern these processes. This innovative approach aims to enhance the efficiency and success rate of drug discovery, allowing for more effective targeting of diseases at the cellular and molecular levels.

Cygnal Therapeutics is developing drugs to manipulate Exoneural Biology for the treatment of cancer, immunological diseases, and regenerative processes. Powered by a comprehensive, cutting-edge neurotechnology platform, They are discovering new dimensions of neural function. Cygnal was founded by Flagship Pioneering in the VentureLabs innovation foundry.

Inari Agriculture, Inc. is a biotechnology company that specializes in developing customized seeds through CRISPR gene editing technology, aimed at optimizing crop growth in diverse environmental conditions. Founded in 2016 and based in Cambridge, Massachusetts, Inari focuses on crops such as wheat, soybean, and corn, addressing significant agricultural challenges like climate change. The company employs advanced multiplex gene editing and predictive design to create efficient and sustainable plant breeding solutions, thereby reducing the time and cost associated with traditional breeding methods. Inari's approach aims to enhance agricultural productivity while respecting environmental sustainability, and it collaborates with a diverse team of scientists and partners globally to drive innovation in the agricultural sector.

Valo Health is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing treatments.

Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Rubius Therapeutics, based in Cambridge, Massachusetts, is focused on developing red cell therapeutics (RCTs) to address severe diseases, including various forms of cancer, enzyme deficiency diseases, and autoimmune disorders. The company's key product candidates include RTX-240 and RTX-224, aimed at treating cancer, as well as RTX-aAPC for both solid and hematological cancers. Additional programs include RTX-321 for HPV-positive tumors and RTX-T1D for type 1 diabetes. Established in 2013, Rubius Therapeutics is pioneering a new class of medicines through its innovative rubius erythrocyte design cellular therapy platform, which leverages previously unexplored scientific concepts to create potential therapeutic solutions.

Inzen Therapeutics is a early-stage biotechnology company exploring cellular turnover as a surprising and important driver of disease.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs.

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing genomic medicines aimed at curing diseases. Founded in 2016, the company utilizes its proprietary epigenomic programming platform to create Omega Epigenomic Controllers. These innovative controllers are designed to selectively modulate the activity of the human genome, allowing for precise tuning of gene expression to achieve therapeutic effects. By targeting specific cell types, Omega Therapeutics aims to transform human medicine through the direct control of genomic functions, offering potential solutions for a variety of diseases.

Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.

Rubius Therapeutics, based in Cambridge, Massachusetts, is focused on developing red cell therapeutics (RCTs) to address severe diseases, including various forms of cancer, enzyme deficiency diseases, and autoimmune disorders. The company's key product candidates include RTX-240 and RTX-224, aimed at treating cancer, as well as RTX-aAPC for both solid and hematological cancers. Additional programs include RTX-321 for HPV-positive tumors and RTX-T1D for type 1 diabetes. Established in 2013, Rubius Therapeutics is pioneering a new class of medicines through its innovative rubius erythrocyte design cellular therapy platform, which leverages previously unexplored scientific concepts to create potential therapeutic solutions.

CIBO Technologies, Inc. is a software company focused on enhancing agricultural practices through advanced modeling and simulation of agricultural ecosystems. The company offers a range of products, including Continuum DB, for spatio-temporal modeling; BarnCAT, a computational agronomy toolkit; and WhetherRain, a stochastic weather generator that provides detailed weather simulations. Additionally, CIBO provides DirtPatch for environmental reconstruction and TerraFarm for planetary-scale simulations. Their Land Intelligence platform generates insights for agricultural stakeholders, including farmers, investors, and lenders, and covers a variety of crops such as corn, soy, and wheat. By combining science, data, and technology, CIBO aims to bring transparency and valuable insights to the agriculture value chain, thereby supporting sustainable practices and informed decision-making across the agricultural landscape. Founded in 2015 and headquartered in Massachusetts, CIBO also maintains offices in Missouri, Michigan, and Minnesota.

Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosisâ„¢ (EOâ„¢) is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Incredible Foods, Inc. manufactures and sells non-dairy frozen products under the brand name perfectlyfree. Its products include fruit bites, frozen bites, and frozen pints. It serves customers through a network of stores. Incredible Foods, Inc. was formerly known as Wikifoods, Inc. and changed its name to Incredible Foods, Inc. in July 2016. The company was founded in 2012 and is based in Boston, Massachusetts. Incredible Foods, Inc. operates as a subsidiary of Quantum Designs, LLC.

Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

TransMedics Group, Inc. is a medical technology company focused on enhancing organ transplant therapies for patients with end-stage organ failure. Headquartered in Andover, Massachusetts, the company has developed the Organ Care System (OCS), a portable technology that maintains donor organs in a near-physiological state during transport. The OCS includes specialized systems for various organs, such as OCS LUNG, which preserves and optimizes lungs; OCS Heart, designed to keep donor hearts metabolically active; and OCS Liver, currently under clinical evaluation for liver transplants. This innovative approach aims to reduce ischemia, improve organ viability, and potentially increase the availability of transplants, addressing critical needs in the field of organ transplantation. TransMedics was founded in 1998 and has positioned itself at the forefront of advancing organ preservation technology.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

TransMedics Group, Inc. is a medical technology company focused on enhancing organ transplant therapies for patients with end-stage organ failure. Headquartered in Andover, Massachusetts, the company has developed the Organ Care System (OCS), a portable technology that maintains donor organs in a near-physiological state during transport. The OCS includes specialized systems for various organs, such as OCS LUNG, which preserves and optimizes lungs; OCS Heart, designed to keep donor hearts metabolically active; and OCS Liver, currently under clinical evaluation for liver transplants. This innovative approach aims to reduce ischemia, improve organ viability, and potentially increase the availability of transplants, addressing critical needs in the field of organ transplantation. TransMedics was founded in 1998 and has positioned itself at the forefront of advancing organ preservation technology.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Rubius Therapeutics, based in Cambridge, Massachusetts, is focused on developing red cell therapeutics (RCTs) to address severe diseases, including various forms of cancer, enzyme deficiency diseases, and autoimmune disorders. The company's key product candidates include RTX-240 and RTX-224, aimed at treating cancer, as well as RTX-aAPC for both solid and hematological cancers. Additional programs include RTX-321 for HPV-positive tumors and RTX-T1D for type 1 diabetes. Established in 2013, Rubius Therapeutics is pioneering a new class of medicines through its innovative rubius erythrocyte design cellular therapy platform, which leverages previously unexplored scientific concepts to create potential therapeutic solutions.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Joule Unlimited, Inc. produces infrastructure-compatible fuels directly from sunlight and waste carbon dioxide. It captures sunlight to produce energy in liquid forms, such as diesel and ethanol, as well as uses waste carbon dioxide as a sole feedstock to produce liquid fuels. Joule Unlimited, Inc. was formerly known as Joule Biotechnologies, Inc. and changed its name to Joule Unlimited, Inc. in 2010. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts with an additional office in Los Angeles, California.

Red Rock Biofuels (RRB) develops processing plants to convert woody biomass into renewable, drop-in diesel and jet fuels. Each refinery is designed to utilize 175,000 dry tons of woody biomass feedstock to produce 16 million gallons per year of finished products. RRB’s technology platform converts woody biomass to jet, diesel, and naphtha fuels. The process begins with the gasification of woody biomass to produce synthesis gas. This synthesis gas is cleaned and sent to a Fischer-Tropsch unit where it is converted to liquid hydrocarbons. Hydroprocessing refines the liquid hydrocarbons to produce jet, diesel, and naptha fuels. Red Rock Biofuels was founded by Jeff Manternach and Terry Kulesa and is based in Colorado, United States.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

EcoSense Lighting is a team of LED lighting pioneers with over 100 years of experience and a genuine passion for delivering advanced solid-state lighting solutions. EcoSense delivers a broad line of high-quality, cutting-edge LED lighting solutions for architectural and commercial applications. EcoSense has a compelling technology portfolio including the new industry-leading breakthrough dimming technology. EcoSense has offices in the United States, the United Kingdom, and Hong Kong with headquarters in Los Angeles.

Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.

Indigo Ag, Inc. operates an online platform that connects farmers with buyers and grain marketing advisors, facilitating the sale of grains. Founded in 2013 and headquartered in Boston, Massachusetts, the company aims to help farmers sustainably enhance their productivity and profitability through the use of beneficial plant microbes. By optimizing crop health and yield, Indigo's offerings enable farmers to implement regenerative agricultural practices while meeting specific buyer requirements for crop quality. The platform also supports growers with year-round partnerships and microbiome treatments tailored to improve farm management. Indigo operates in various locations worldwide, including Memphis, Research Triangle Park, Sydney, Buenos Aires, São Paulo, Basel, and Mumbai, reflecting its commitment to serving the agricultural community globally.

Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.

Selecta Biosciences is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company’s proprietary platform integrates advancements in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates, including SEL-302 and SEL-313, which are in preclinical development for rare metabolic disorders. The company has established collaborations and licensing agreements with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences continues to innovate in the biopharmaceutical field.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.

Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.

Tarveda Therapeutics, Inc. develops cancer therapies that address the challenges of treating solid tumors. It offers Pentarin, a miniature drug conjugate medicine for the treatment of patients with solid tumor malignancies. Tarveda Therapeutics, Inc. was formerly known as Blend Therapeutics, Inc. and changed its name to Tarveda Therapeutics, Inc. in January 2016. The company was founded in 2011 and is based in Watertown, Massachusetts.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.

EcoSense Lighting is a team of LED lighting pioneers with over 100 years of experience and a genuine passion for delivering advanced solid-state lighting solutions. EcoSense delivers a broad line of high-quality, cutting-edge LED lighting solutions for architectural and commercial applications. EcoSense has a compelling technology portfolio including the new industry-leading breakthrough dimming technology. EcoSense has offices in the United States, the United Kingdom, and Hong Kong with headquarters in Los Angeles.

Axcella Health Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializing in the research and development of endogenous metabolic modulators (EMMs) to address complex diseases and enhance overall health. The company focuses on amino acid homeostasis and has identified over 2,000 diseases linked to amino acid imbalances. Axcella has developed a systems pharmacology approach to restore health at the cellular level, leading to a range of clinical-stage candidates targeting conditions such as hepatic encephalopathy, non-alcoholic steatohepatitis, muscle atrophy, and various biological pathways related to blood health. Founded in 2008 and previously known as Newco LS16, Inc., Axcella aims to pioneer innovative treatments that have the potential to significantly impact the therapeutic landscape.

Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Medical device and pharmaceutical company advancing the science and technology of corneal cross-linking

Moderna, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2010. It specializes in the development of therapeutics and vaccines utilizing messenger RNA technology, which instructs cells to produce proteins essential for various biological functions. The company's extensive pipeline includes 40 mRNA development candidates targeting a range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. Moderna gained significant recognition with its COVID-19 vaccine, which was authorized for use in the United States in December 2020. The company maintains strategic partnerships with organizations such as AstraZeneca, Merck & Co., and the Bill & Melinda Gates Foundation, enhancing its research capabilities and manufacturing processes. Additionally, it has research collaborations with esteemed institutions like Harvard University.

Seres Health, now known as Seres Therapeutics, Inc., is a clinical-stage therapeutics company focused on the development of microbiome-based drugs aimed at treating various diseases associated with dysbiosis. The company specializes in Ecobiotic therapeutics designed to restore health by repairing the microbiome's function. Its lead product candidate, SER-109, is currently in Phase III clinical trials to prevent the recurrence of Clostridium difficile infection (CDI). Additionally, Seres is advancing several other candidates, including SER-287, which is in a Phase IIb study for ulcerative colitis, and SER-401, currently in Phase Ib trials for use in combination with checkpoint inhibitors in metastatic melanoma patients. Other candidates under development include SER-262 for initial CDI recurrence and SER-155 for modulating the microbiome in patients post-stem cell transplants. The company collaborates with organizations like Nestec Ltd. and Memorial Sloan Kettering Cancer Center, and was founded in 2010 in Cambridge, Massachusetts.

TransMedics Group, Inc. is a medical technology company focused on enhancing organ transplant therapies for patients with end-stage organ failure. Headquartered in Andover, Massachusetts, the company has developed the Organ Care System (OCS), a portable technology that maintains donor organs in a near-physiological state during transport. The OCS includes specialized systems for various organs, such as OCS LUNG, which preserves and optimizes lungs; OCS Heart, designed to keep donor hearts metabolically active; and OCS Liver, currently under clinical evaluation for liver transplants. This innovative approach aims to reduce ischemia, improve organ viability, and potentially increase the availability of transplants, addressing critical needs in the field of organ transplantation. TransMedics was founded in 1998 and has positioned itself at the forefront of advancing organ preservation technology.

Quanterix Corporation specializes in single-molecule analysis, offering a platform that significantly enhances sensitivity, precision, and robustness in clinical diagnostics, drug development, and life science research. Their technology enables rapid quantification and analysis of individual proteins and small molecules within complex biological samples, addressing various unmet medical needs. The ultra-sensitive detection solution, Simoa, allows researchers to closely examine biomarkers' roles in health and disease, facilitating earlier disease detection, improved prognosis, and more precise treatment methods. Founded in 2007, Quanterix is supported by prominent life science investors, aiming to improve the quality of life and longevity for future generations through advanced diagnostic capabilities.

Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.